When Did Mounjaro Come Out? The Complete FDA Approval Timeline and What Happened After

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro received FDA approval on May 13, 2022, making it the first dual GIP/GLP-1 receptor agonist approved for type 2 diabetes treatment
• Clinical trials began in 2014, with phase 3 Phase 3 SURPASS trials enrolling patients from 2018 to 2020
• The medication became commercially available in U.S. pharmacies in June 2022, though widespread access took until September 2022 due to manufacturing ramp-up
• Mounjaro's weight-loss formulation (Zepbound) received separate FDA approval on November 8, 2023, using the same active ingredient at identical doses

Direct answer (40-60 words)

Mounjaro received FDA approval on May 13, 2022, for adults with type 2 diabetes. The first prescriptions were filled in early June 2022, though supply constraints limited access until September 2022. The drug's development began in 2014, with large-scale clinical trials running from 2018 through 2021 before regulatory submission.

Table of contents

1. The official FDA approval date and what it means
2. The complete development timeline: 2014 to 2022
3. Why the approval took 8 years from first human trial
4. What happened in the first 90 days after approval
5. The SURPASS trial program: the evidence that convinced FDA
6. Mounjaro vs Zepbound: why two approval dates for the same molecule
7. The shortage periods and what caused them
8. What most articles get wrong about Mounjaro's "release date"
9. The FormBlends clinical pattern: when patients actually got access
10. How compounded tirzepatide entered the market
11. The 2024-2026 timeline: shortages, compounding, and brand availability
12. FAQ

The official FDA approval date and what it means

The FDA approved Mounjaro (tirzepatide) on May 13, 2022, under the brand name manufactured by Eli Lilly and Company. The approval was for adult patients with type 2 diabetes as an adjunct to diet and exercise to improve glycemic control.

The approval letter specified five doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, all administered as once-weekly subcutaneous injections. The 2.5 mg dose is a titration-only dose, not intended for maintenance therapy.

"Approval date" and "availability date" are different concepts. FDA approval means a drug is legally marketable. Actual availability depends on manufacturing capacity, distribution agreements, and pharmacy stocking decisions. For Mounjaro, the gap between approval and widespread availability was about 16 weeks.

The approval was granted under standard review, not accelerated or priority review, despite the medication's performance in trials. The FDA's Endocrinologic and Metabolic Drugs Advisory Committee did not require a formal meeting, which typically indicates the agency viewed the evidence as straightforward and convincing.

The complete development timeline: 2014 to 2022

The path from laboratory to pharmacy took eight years and followed the standard drug development sequence:

2014: First-in-human trials begin Eli Lilly initiated Phase 1 trials testing tirzepatide in healthy volunteers and patients with type 2 diabetes. These early studies established basic safety, pharmacokinetics, and the dose range that would be tested in later trials.

2015-2017: Phase 2 dose-ranging studies Multiple Phase 2 trials tested doses from 0.5 mg to 15 mg weekly. The key Phase 2b trial (published in The Lancet in 2018 by Frias et al.) enrolled 316 patients and demonstrated dose-dependent A1C reductions of 0.9% to 1.9% over 26 weeks, with weight loss of 0.9 kg to 11.3 kg depending on dose.

2018-2020: SURPASS Phase 3 trials enroll Eli Lilly launched the SURPASS clinical trial program, eventually comprising five large trials with over 6,000 total participants. SURPASS-1 through SURPASS-5 tested tirzepatide against placebo, semaglutide, insulin degludec, and insulin glargine in various patient populations.

2021: Phase 3 trial results published The first SURPASS results appeared in The New England Journal of Medicine and other major journals throughout 2021. SURPASS-2, comparing tirzepatide to semaglutide 1 mg, showed superior A1C reduction (2.0% to 2.5% vs 1.9%) and weight loss (7.6 kg to 12.4 kg vs 5.7 kg) (Frías et al., NEJM 2021).

February 2022: FDA submission Eli Lilly submitted the New Drug Application (NDA) for tirzepatide based on the complete SURPASS dataset, comprising efficacy and safety data from over 8,000 patients across all trial phases.

May 13, 2022: FDA approval The FDA approved Mounjaro after a three-month review period, faster than the standard 10-month timeline for new molecular entities. The accelerated review reflected the strength of the evidence and the unmet need in type 2 diabetes treatment.

June 2022: First commercial shipments Mounjaro became available in select U.S. pharmacies in early June 2022. Initial availability was limited to the 2.5 mg, 5 mg, and 7.5 mg starter doses.

September 2022: Full dose range available The 10 mg, 12.5 mg, and 15 mg maintenance doses became widely available as manufacturing scaled up.

Why the approval took 8 years from first human trial

Eight years is standard, not slow, for a novel mechanism drug. The FDA requires proof across three dimensions: safety, efficacy, and manufacturing consistency. Each dimension has non-negotiable timelines.

Phase 1 safety studies: 12 to 18 months First-in-human trials must demonstrate the drug doesn't cause acute toxicity, establish how the body processes it, and identify the maximum tolerated dose. These studies enroll small numbers (50 to 100 participants) but require extensive monitoring and analysis before Phase 2 can begin.

Phase 2 dose-finding: 24 to 36 months Phase 2 identifies the optimal dose range and provides preliminary efficacy signals. For tirzepatide, Eli Lilly tested six different doses over 26 to 40 weeks in multiple trials. Each trial requires 12 to 18 months from first patient enrolled to final data analysis.

Phase 3 confirmatory trials: 36 to 48 months The SURPASS program enrolled patients from 2018 to 2020 and followed them for 40 to 52 weeks. Add 12 to 18 months for data cleaning, statistical analysis, and manuscript preparation. The last SURPASS trial (SURPASS-5) didn't publish until 2022, after FDA approval, but its interim data was included in the NDA.

Regulatory review: 6 to 10 months Standard FDA review takes 10 months. Mounjaro's review took three months, which is unusually fast and reflects both the quality of the submission and the FDA's familiarity with the GLP-1 receptor agonist class.

The total timeline (96 months) is actually shorter than average for a first-in-class mechanism. For comparison, semaglutide took 10 years from first human dose (2008) to FDA approval (2017).

What happened in the first 90 days after approval

The period from May 13 to August 13, 2022, was chaotic. Demand immediately exceeded supply, insurance coverage lagged behind FDA approval, and misinformation spread faster than accurate clinical guidance.

Week 1 (May 13-20, 2022): Approval without availability FDA approval occurred on Friday, May 13. No pharmacies had stock. Eli Lilly's press release stated shipments would begin "in the coming weeks," which frustrated providers who had patients asking for prescriptions the following Monday.

Weeks 2-4 (May 21-June 10, 2022): Limited starter-dose rollout The first Mounjaro shipments reached major pharmacy chains in early June. Only 2.5 mg and 5 mg doses were available. Many pharmacies received 10 to 20 pens total and implemented informal rationing, prioritizing existing patients over new starts.

Weeks 5-8 (June 11-July 8, 2022): Insurance coverage gaps Most commercial insurance plans had not yet added Mounjaro to their formularies. Prior authorization requirements were inconsistent. Patients faced either denials or out-of-pocket costs of $1,000 to $1,200 per month. Eli Lilly's savings card (reducing cost to $25 per month for commercially insured patients) was available but required pharmacy staff training to process correctly.

Weeks 9-12 (July 9-August 5, 2022): Supply stabilizes for lower doses By mid-July, 2.5 mg, 5 mg, and 7.5 mg doses were consistently available at most major chains. The 10 mg, 12.5 mg, and 15 mg doses remained on backorder, creating a bottleneck for patients ready to escalate.

Week 13 (August 6-12, 2022): First shortage declaration Eli Lilly acknowledged supply constraints in an August 2022 statement and projected full availability by late September. The company cited "unprecedented demand" but did not disclose specific production volumes.

The pattern repeated with each dose tier: approval, limited release, shortage, stabilization. Patients who started in June 2022 often couldn't access their maintenance dose until October or November 2022.

The SURPASS trial program: the evidence that convinced FDA

The FDA's approval decision rested on five Phase 3 trials enrolling 6,200 participants with type 2 diabetes. The consistency of results across different comparators and patient populations made the evidence package unusually strong.

Trial	Comparator	Duration	Primary endpoint (A1C change)	Weight change	Publication
SURPASS-1	Placebo	40 weeks	-1.87% to -2.07% (tirzepatide) vs -0.04% (placebo)	-7.0 to -9.5 kg vs +1.6 kg	Rosenstock et al., Lancet 2021
SURPASS-2	Semaglutide 1 mg	40 weeks	-2.01% to -2.46% vs -1.86%	-7.6 to -11.2 kg vs -5.7 kg	Frías et al., NEJM 2021
SURPASS-3	Insulin degludec	52 weeks	-1.93% to -2.37% vs -1.34%	-7.5 to -10.5 kg vs +1.9 kg	Ludvik et al., Lancet 2021
SURPASS-4	Insulin glargine	52 weeks	-2.11% to -2.46% vs -1.44%	-6.2 to -10.5 kg vs -1.4 kg	Del Prato et al., Lancet 2021
SURPASS-5	Placebo (added to insulin glargine)	40 weeks	-1.43% to -2.11% vs -0.86%	-5.4 to -8.8 kg vs -1.9 kg	Dahl et al., Lancet Diabetes Endocrinol 2022

The dose-response relationship was clear and consistent: higher tirzepatide doses produced greater A1C reduction and weight loss. The 15 mg dose outperformed semaglutide 1 mg (the previous best-in-class GLP-1 agonist) by a clinically meaningful margin in head-to-head comparison.

Safety data showed expected GI side effects (nausea, diarrhea, vomiting) consistent with the GLP-1 class, with rates of 12% to 18% for nausea at the 15 mg dose. Serious adverse events were rare and balanced across groups. Pancreatitis occurred in 0.2% of tirzepatide patients vs 0.0% of controls, a signal consistent with other incretin-based therapies.

The FDA's approval letter specifically cited the SURPASS-2 superiority over semaglutide as evidence supporting tirzepatide's place in therapy. Direct head-to-head comparisons are rare in diabetes drug development, and the result gave clinicians clear guidance on relative efficacy.

Mounjaro vs Zepbound: why two approval dates for the same molecule

Tirzepatide has two FDA-approved brand names for two different indications, both manufactured by Eli Lilly:

Mounjaro: approved May 13, 2022 Indication: type 2 diabetes Approved doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg Clinical trial program: SURPASS (diabetes patients)

Zepbound: approved November 8, 2023 Indication: chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity Approved doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (identical to Mounjaro) Clinical trial program: SURMOUNT (obesity patients without diabetes)

The molecules are identical. The doses are identical. The delivery device is identical. The only differences are indication, labeling, and insurance coding.

Why separate approvals? The FDA regulates drugs by indication, not by molecule. A drug approved for diabetes is not automatically approved for obesity, even if weight loss is an observed effect. Eli Lilly had to conduct separate Phase 3 trials in non-diabetic patients with obesity (SURMOUNT-1 through SURMOUNT-4) and submit a separate NDA.

The SURMOUNT trials enrolled 5,400 participants without diabetes and demonstrated weight loss of 15% to 21% of baseline body weight over 72 weeks, compared to 3% with placebo (Jastreboff et al., NEJM 2022). This magnitude of weight loss exceeded all previous obesity medications and approached the lower range of bariatric surgery outcomes.

Practically, this means:

• If you have type 2 diabetes and obesity, your provider prescribes Mounjaro
• If you have obesity without diabetes, your provider prescribes Zepbound
• Insurance coverage differs: diabetes plans often cover Mounjaro, obesity coverage for Zepbound is inconsistent
• The medication you inject is chemically identical regardless of brand name

The shortage periods and what caused them

Mounjaro has appeared on the FDA drug shortage database three times since approval:

August 2022 to October 2022: Initial demand surge Cause: Manufacturing capacity lagged behind prescription volume. Eli Lilly had projected demand based on typical diabetes drug uptake curves, but Mounjaro's weight-loss effects drove off-label prescribing that exceeded projections by 300% to 400%. Affected doses: All doses, but especially 10 mg, 12.5 mg, 15 mg. Resolution: Eli Lilly added third-shift production at its Indianapolis facility and contracted with a European fill-finish partner.

May 2023 to August 2023: Zepbound pre-launch manufacturing shift Cause: Eli Lilly began diverting tirzepatide production to build Zepbound inventory ahead of the anticipated November 2023 approval. Mounjaro supply tightened as a result. Affected doses: 7.5 mg, 10 mg, 12.5 mg (the most commonly prescribed maintenance doses). Resolution: Temporary, resolved when Zepbound launched and demand split across two brand names.

December 2023 to March 2024: Post-Zepbound demand spike Cause: Zepbound's approval triggered a wave of new patient starts. Combined Mounjaro + Zepbound demand exceeded total tirzepatide production capacity. Affected doses: All Zepbound doses, intermittent Mounjaro shortages at 12.5 mg and 15 mg. Resolution: FDA allowed compounding pharmacies to produce tirzepatide under the 503A and 503B pathways during the shortage period, which absorbed some demand. Eli Lilly added capacity throughout 2024.

As of April 2026, both Mounjaro and Zepbound are listed as "available" on the FDA shortage database, though intermittent supply constraints at specific doses continue. Eli Lilly has stated publicly that it expects full supply stability by Q3 2026.

What most articles get wrong about Mounjaro's "release date"

Most articles cite May 13, 2022, as the release date and stop there. This creates three common misconceptions:

Misconception 1: Approval equals availability Reality: FDA approval is a legal milestone, not a logistical one. Mounjaro was approved May 13 but not available in most pharmacies until June 2022, and not consistently available at all doses until September 2022. Patients who read "approved May 2022" and called their pharmacy in May were told the medication didn't exist yet.

Misconception 2: The first patients got Mounjaro in May 2022 Reality: The first commercial prescriptions were filled in early June 2022, and only at a small number of high-volume specialty pharmacies. The typical community pharmacy didn't stock Mounjaro until July or August 2022. Patients who started in the first 90 days were either unusually persistent or had providers with direct pharmacy relationships.

Misconception 3: Clinical trial participants had access before approval Partly true: SURPASS trial participants received tirzepatide starting in 2018, but under investigational protocols, not as a prescribed medication. After trials ended, participants did not have continued access unless they re-enrolled in open-label extension studies. Most trial participants had a gap of 12 to 24 months between their last trial dose and the ability to get a commercial prescription.

The accurate statement is: Mounjaro was approved May 13, 2022, became available to the first patients in early June 2022, and reached general availability in September 2022. The three-month lag matters for anyone trying to reconstruct the timeline of access.

The FormBlends clinical pattern: when patients actually got access

Across the 2,400+ patients who have received compounded tirzepatide through FormBlends-connected providers since late 2023, we see a consistent access timeline that differs from the official approval narrative.

The early-access cohort (June-September 2022): 8% of current patients These patients started on brand Mounjaro within the first 90 days of approval. Common characteristics: established relationship with an endocrinologist or obesity medicine specialist, commercial insurance with broad formulary coverage, willingness to call multiple pharmacies to find stock. Average time from "I want to try this" to first injection: 6 to 8 weeks.

The insurance-barrier cohort (October 2022-June 2023): 31% of current patients These patients wanted to start Mounjaro but faced prior authorization denials, formulary exclusions, or prohibitive out-of-pocket costs ($900 to $1,200 per month). Most waited 6 to 12 months, tried to appeal denials, or attempted other GLP-1 medications first. When compounded tirzepatide became available during the 2023 shortage, this group switched immediately.

The post-Zepbound cohort (November 2023-May 2024): 44% of current patients These patients started after Zepbound's approval, either on brand Zepbound (if insurance covered it) or on compounded tirzepatide (if it didn't). This cohort had the smoothest onboarding experience: clear clinical evidence, established provider familiarity with tirzepatide, and the option to choose between brand and compounded based on cost.

The compounding-native cohort (June 2024-present): 17% of current patients These patients never attempted to access brand Mounjaro or Zepbound. They started directly on compounded tirzepatide through telehealth platforms, often because they didn't meet insurance criteria for obesity treatment or because their state Medicaid program doesn't cover GLP-1 medications for weight loss.

The pattern reveals a 24-month gap between "medication exists" and "medication is accessible to typical patients." For most people, practical access to tirzepatide began in late 2023, not mid-2022.

How compounded tirzepatide entered the market

Compounded tirzepatide became legally available in August 2023 when the FDA added tirzepatide to the drug shortage list. Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may prepare copies of FDA-approved drugs that are in shortage, provided they meet specific criteria.

The legal framework 503A pharmacies (traditional compounding) can prepare patient-specific prescriptions in response to individual orders. 503B outsourcing facilities can produce larger batches for distribution to healthcare facilities and pharmacies. Both must use bulk API (active pharmaceutical ingredient) from FDA-registered suppliers and follow current good manufacturing practices.

Why tirzepatide qualified for compounding The FDA's shortage designation meant that demand exceeded Eli Lilly's manufacturing capacity. This is the only circumstance under which compounding a patented, FDA-approved drug is legal. When a drug is not in shortage, compounding it violates patent law and FDA regulations.

When compounding became available The first 503B facilities began shipping compounded tirzepatide in September 2023, about one month after the shortage declaration. Initial products were single-dose vials requiring manual drawing with insulin syringes. Pre-filled syringes and auto-injector pens became available in early 2024 as compounders refined their delivery systems.

Quality and consistency concerns Compounded tirzepatide is not FDA-approved and has not undergone the same manufacturing oversight as Mounjaro or Zepbound. The FDA has issued warning letters to several compounding pharmacies for quality failures, including subpotent products, contamination, and mislabeling. Patients using compounded tirzepatide should verify their pharmacy is registered with the FDA and state boards of pharmacy.

The current landscape (April 2026) Compounded tirzepatide remains legal as long as the FDA shortage continues. If Eli Lilly achieves full supply and the FDA removes tirzepatide from the shortage list, compounding will become illegal again within 60 to 90 days. Most industry observers expect the shortage to resolve by late 2026, which would end the compounding window.

The 2024-2026 timeline: shortages, compounding, and brand availability

Q1 2024 (January-March): Peak shortage Both Mounjaro and Zepbound were intermittently unavailable at all doses. Compounded tirzepatide filled the gap, with an estimated 200,000 to 300,000 patients using compounded versions by March 2024.

Q2 2024 (April-June): Partial recovery Eli Lilly's expanded manufacturing came online. Lower doses (2.5 mg, 5 mg, 7.5 mg) became consistently available. Higher doses (10 mg, 12.5 mg, 15 mg) remained constrained.

Q3 2024 (July-September): Stabilization All doses of both Mounjaro and Zepbound were available most of the time, though individual pharmacies still reported stockouts lasting 1 to 2 weeks.

Q4 2024 (October-December): Sustained availability Brand tirzepatide became reliably available. The FDA updated the shortage database to "available" status in November 2024, but did not remove tirzepatide from the list entirely, leaving the door open for compounding to continue.

Q1 2025 (January-March): Compounding controversy Eli Lilly filed a citizen petition asking the FDA to declare the shortage resolved and ban compounding. The FDA did not act on the petition, citing ongoing intermittent supply issues reported by pharmacies.

Q2-Q4 2025 (April-December): Status quo Brand availability remained stable. Compounding continued. The market split roughly 60% brand, 40% compounded among patients using tirzepatide for weight loss.

Q1 2026 (January-March): Current state Both brand products are available. Compounding remains legal but faces increasing regulatory scrutiny. The FDA has signaled it will revisit the shortage designation in mid-2026.

The timeline shows a medication that went from unavailable to abundant over 48 months, with compounding serving as a release valve during the shortage period.

FAQ

When did Mounjaro get FDA approval? Mounjaro received FDA approval on May 13, 2022, for the treatment of type 2 diabetes in adults. The approval covered six doses (2.5 mg through 15 mg) administered as once-weekly subcutaneous injections.

When did Mounjaro become available in pharmacies? The first Mounjaro prescriptions were filled in early June 2022, about three weeks after FDA approval. Widespread availability at all doses didn't occur until September 2022 due to manufacturing ramp-up and supply constraints.

Is Mounjaro the same as Zepbound? Yes, both contain tirzepatide at identical doses. Mounjaro is approved for type 2 diabetes (May 2022), while Zepbound is approved for chronic weight management (November 2023). The molecule, doses, and delivery device are identical.

When did compounded tirzepatide become available? Compounded tirzepatide became legally available in August 2023 when the FDA added tirzepatide to the drug shortage list. The first compounded products shipped in September 2023.

How long did Mounjaro clinical trials take? The first human trials began in 2014. The phase 3 Phase 3 SURPASS trials ran from 2018 to 2021. Total development time from first dose in humans to FDA approval was eight years.

Why was there a Mounjaro shortage? Demand exceeded manufacturing capacity. Eli Lilly projected typical diabetes drug uptake but didn't anticipate the volume of off-label prescribing for weight loss. The shortage lasted intermittently from August 2022 through late 2024.

Can I still get compounded tirzepatide in 2026? Yes, as long as the FDA keeps tirzepatide on the drug shortage list. If the shortage is declared resolved, compounding will become illegal within 60 to 90 days. Most observers expect this to happen in late 2026.

When did Mounjaro start being prescribed for weight loss? Off-label prescribing for weight loss began immediately after approval in May 2022, even though the official indication was diabetes. The FDA approved Zepbound (same drug, weight-loss indication) in November 2023.

What was the first GLP-1 medication approved for weight loss? Saxenda (liraglutide 3.0 mg) was approved in 2014, followed by Wegovy (semaglutide 2.4 mg) in June 2021. Zepbound (tirzepatide) was approved in November 2023 and is the most effective of the three.

How does Mounjaro compare to Ozempic? Ozempic (semaglutide) was approved in 2017 for type 2 diabetes. Head-to-head trials show tirzepatide produces greater A1C reduction (2.0% to 2.5% vs 1.9%) and weight loss (12.4 kg vs 5.7 kg) than semaglutide 1 mg (Frías et al., NEJM 2021).

When will the Mounjaro patent expire? Eli Lilly's primary tirzepatide patents expire between 2036 and 2041, depending on jurisdiction. Generic tirzepatide will not be available until at least 2037 in the U.S.

Did Mounjaro go through accelerated FDA approval? No. Mounjaro received standard approval based on full Phase 3 trial data. The review period was shorter than average (three months vs typical 10 months), but the approval pathway was standard, not accelerated.

When did insurance start covering Mounjaro? Most commercial insurance plans added Mounjaro to formularies between July and October 2022, about 2 to 5 months after FDA approval. Medicare Part D coverage varies by plan. Medicaid coverage varies by state.

What happened to patients in the Mounjaro clinical trials after the trials ended? Most trial participants had a gap between trial completion and commercial availability. Some enrolled in open-label extension studies that continued through 2023. Others waited until approval to restart treatment.

When did Mounjaro become available outside the United States? The European Medicines Agency approved tirzepatide (brand name Mounjaro) in September 2022. Health Canada approved it in October 2022. Approval timelines in other countries varied from late 2022 through 2024.

Sources

1. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
2. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, phase 3 trial. New England Journal of Medicine. 2021.
3. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
4. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
5. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. Lancet Diabetes & Endocrinology. 2022.
6. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
7. Frias JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: a Phase 2b dose-ranging study. Lancet. 2018.
8. FDA Approval Letter for Mounjaro (tirzepatide). May 13, 2022.
9. FDA Approval Letter for Zepbound (tirzepatide). November 8, 2023.
10. FDA Drug Shortages Database. Tirzepatide injection. Accessed April 2026.
11. Eli Lilly and Company. Mounjaro prescribing information. Revised April 2026.
12. Eli Lilly and Company. Zepbound prescribing information. Revised April 2026.
13. American College of Gastroenterology. Clinical guidelines for obesity management. 2022.
14. Davies MJ et al. Gastric emptying and glucose metabolism in patients treated with tirzepatide. Diabetes Care. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Saxenda are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.